Exchange: NASDAQ·Updated 05:02 PM EST
KPRX logo

KPRX Kiora Pharmaceuticals Inc

$0.73
$0.1008
(12.28%)
Today
Closed $0.7202
$0.0098
(1.36%)
After Hours
Reported EarningsNov 12
Mkt Cap$3.19M
Vol64,688.00

About KPRX

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.
39

Bearish Sentiment

How do you feel about KPRX?

Bohrenn
Sharedeals.de No Brainer Club: $KPRX: Am 20.02.2026 Kaufzone von 2,30 USD, seit Empfehlung −64,3 %; mega Verluste auch hier, aber natürlich alles: unfassbare Chancen
3
Biotech_Pharma_Investor
$KPRX how do they plan to fund the deal if price falls below Tranche A warrants price?? Lower repricing?...
1
Biotech_Pharma_Investor
$KPRX not a great deal... Spending all tranche 1 warrants (1.92 strike price) cash for the acquisition, dropping an asset and in need of cash for the ph3 program (= more dilution...). I even wonder whether stock will be pumped enough to allow warrants exercise... KPRX has gotten much riskier (unless more institutional support appears)
1
romarcin23
$KPRX Discussing the 401 acquisition. Is it just me or is this the most non-answer in human history?
romarcin23
$KPRX The downward spiral continues. Would have been better to cancel the 104 if the results looked equivocal and simply awaited the 301 data before spending money they do not have to fund a phase 3 trial. Seriously, what naive person is making these silly decisions ?
romarcin23
$KPRX Whoa! I guess the 104 results must have been bad. It was not blinded study so kiora has been viewing the results as they come it, low enrolment combined with poor early data caused them to pull the plug and swerve to 401? Is this a downward spiral? Same situation as the 101
Biotech_Pharma_Investor
$KPRX The FDA Gold-Standard Endpoint (3-Line / \ge 15-Letter Gain) Missed in BOTH Analyses (p = 0.582 and p = 0.158). + Nearly one-quarter of the placebo arm (8/33) is missing . 9.1% (3 of 33) missing from treatment arm + 91% of the trial (50\text{ out of }55\text{ patients}) was ALREADY in the "worse than 20/400" subgroup

Advertisement|Remove ads.